The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 67-70

  Thompson, Gilbert R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Coronary heart disease; Hypercholesterolaemia; Lipoprotein(a)

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANGIOGRAPHY; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CORRELATION ANALYSIS; DRUG MEGADOSE; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; LIPOPROTEIN APHERESIS; LIPOPROTEIN BLOOD LEVEL; MEDICAL LITERATURE; MEDLINE; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW;

BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; EVIDENCE-BASED MEDICINE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; HYPOLIPIDEMIC AGENTS; LIPOPROTEIN(A); LIPOPROTEINS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872835004     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.001     Document Type: Article

References (20)

1. Thompson G.R., Barbir M., Davies D., et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010, 208:317-321.
2. Thompson G.R., Barbir M., Davies D., et al. Recommendations for the use of LDL apheresis. Atherosclerosis 2008, 198:247-255.
3. Kolansky D.M., Cuchel M., Clark B.J., et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008, 102:1438-1443.
4. Palcoux J.-B., Atassi-Dumont M., Lefevre P., et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial 2008, 12:195-201.
5. Hudgins L., Kleimann B., Scheuer A., White S., Gordon B.R. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 2008, 102:1199-1204.
6. Thompson G.R., Miller J.P., Breslow J.L. Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Br Med J 1985, 291:1671-1673.
7. Keller C. LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience. Atheroscler Suppl 2009, 10:21-26.
8. Raal F.J., Pilcher G.J., Panz V.R., et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011, 124:2202-2207.
9. Thompson G.R., Maher V.M., Matthews S., et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995, 345:811-816.
10. Kroon A.A., Aengevaeren W.R., van der Werf T., et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996, 93:1826-1835.
11. Nishimura S., Sekiguchi M., Kano T., et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 1999, 144:409-417.
12. Mabuchi H., Koizumi J., Shimizu M., et al. Hokuriku-FH-LDLApheresis Study Group. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998, 82:1489-1495.
13. Armstrong V.W., Cremer P., Eberle E., et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 1986, 62:249-257.
14. Jaeger B., Richter Y., Nagel D., et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009, 6:229-239.
15. Emerging Risk Factors Collaboration Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423.
16. Koziolek M.J., Hennig U., Zapf A., et al. Retrospective analysis of long-term lipid apheresis at a single center. Ther Apher Dial 2009, 14:143-152.
17. Civeira F. International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004, 173:55-68.
18. Nordestgaard B.G., Chapman M.J., Ray K., et al. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853.
19. NICE Clinical Guideline 71 Identification and management of familial hypercholesterolaemia August 2008.
20. McKenney J.M., Koren M.J., Kerelakes D.J., et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serum protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012, 59:2344-2353.